Biochemistry Analyzers in Massachusetts

Diamond Diagnostics Inc. is a specialized clinical laboratory instrumentation and consumables supplier based in Holliston, Massachusetts, founded in 1996. The company manufactures, remanufactures, and supplies new and refurbished chemistry analyzers, electrolyte analyzers, immunoassay systems, blood gas analyzers, coagulation analyzers, hematology analyzers, and molecular analyzers. With approximately 80 employees and ~$19M annual revenue, Diamond offers over 500 consumable products including reagents, quality controls, and electrodes. The company's proprietary Down-To-Frame® refurbishment process restores equipment to like-new condition. Most products hold FDA clearance and CE approval. Diamond provides comprehensive field service, depot service, preventive maintenance, remote support, control assay, and refurbishment services to clinical laboratories and hospitals globally. ISO 9001:2015 and ISO 13485:2016 certified, the company also offers OEM and contract manufacturing for third-party organizations.

Werfen is a global in vitro diagnostics company operating directly in over 30 countries and through distributors in more than 100 territories. The company develops, manufactures, and commercializes diagnostic systems, reagents, software, and services across hemostasis, acute care diagnostics, transfusion, autoimmunity, transplant, immunoassay, and clinical chemistry. Werfen's hemostasis portfolio includes in vitro diagnostic systems and reagents for diagnosing and guiding treatment of thrombotic and bleeding disorders. The acute care diagnostics line provides integrated whole-blood testing solutions for cardiovascular operating rooms, catheterization laboratories, intensive care units, and emergency departments. The transfusion division offers manual and automated solutions with serology reagents, fully automated instrumentation, data management software, and molecular products for donor-recipient compatibility. The autoimmunity segment delivers reagents and lab automation for diagnosing and monitoring autoimmune diseases. Transplant products feature molecular and antibody-based HLA assays and software for pretransplant compatibility determination and post-transplant monitoring. Clinical chemistry solutions serve chemistry and pharma-toxicology laboratories. Werfen also recently completed the acquisition of Omixon, a Budapest-based company specializing in next-generation sequencing technologies for transplant diagnostics. The company maintains a technology center in Bedford, Massachusetts, expanded in December 2024. Werfen's solutions are designed to improve patient care quality, reduce laboratory costs, ensure regulatory compliance, and enhance operational efficiency across clinical laboratory and acute care hospital settings.

High Technology, Inc. (HTI) manufactures laboratory analyzers engineered specifically for emerging healthcare systems and resource-constrained environments. The company specializes in clinical diagnostic equipment including hematology, clinical chemistry, electrolyte, urinalysis, and coagulation analyzers. HTI's core value proposition centers on delivering reliable diagnostic performance in real-world conditions—fluctuating power supply, varying ambient temperatures, and challenging infrastructure—without requiring ideal laboratory conditions. Products feature intuitive touchscreen interfaces with multilingual support, role-based access controls, and are designed for operation across diverse skill levels. HTI operates a distributor-partnership model, offering exclusive territorial agreements, factory training and certification programs, protected distribution channels, and regional support teams across Africa, Latin America, Asia, and Eastern Europe. The company also manufactures veterinary diagnostic analyzers using the same robust, real-world-focused engineering principles. Products mentioned include the HTI MicroCC-25 Plus, a 5-part hematology analyzer designed for community outpatient labs, rural clinics, district hospitals, and maternal health programs. HTI emphasizes consistent reagent supply chains, data protection, and sustainable local partnerships rather than treating distributors as replaceable sales channels. The organization positions itself as a healthcare infrastructure builder serving mid-market and emerging-economy clinical settings.

Nova Biomedical is a privately held, globally-leading in vitro diagnostic (IVD) company founded in 1976 and headquartered in Waltham, Massachusetts. The largest privately owned diagnostic company in the United States, Nova Biomedical employs over 1,500 people across manufacturing facilities in Massachusetts and Taipei, Taiwan, serving 110+ countries through its global distributor network. The company specializes in advanced blood testing and analytical instrumentation, with a comprehensive portfolio including critical care blood gas analyzers (StatProfile® Prime series), point-of-care glucose meters (StatStrip®, NovaMax®), cell culture analyzers (BioProfile® Flex), clinical and bioprocessing osmometers, liquid volume verification systems, and automated CSF cell counters. Nova Biomedical serves hospitals, emergency departments, blood banks, biotech/pharmaceutical manufacturers, clinical research laboratories, and veterinary diagnostics markets. The company operates through multiple trusted brand portfolios including Advanced Instruments, BioProfile, StatProfile, StatStrip, Artel, Solentim, and GloCyte, delivering solutions for bioprocessing, clinical diagnostics, and veterinary applications with emphasis on improving patient outcomes and operational efficiency.

SEKISUI Diagnostics is a global leader in diagnostic reagents, biochemistry products, and point-of-care testing solutions with over 40 years of industry experience. The company manufactures and supplies clinical chemistry reagents, performing over 1.8 billion tests annually worldwide. Core product lines include Clinical Chemistry reagents for laboratory analyzers, Point-of-Care Testing (POCT) solutions in multiple formats to enable rapid diagnosis in office and clinic settings, and specialty biochemical enzymes for diagnostic reagent and biosensor manufacturers. SEKISUI also provides Blood Collection Tube Raw Materials and pre-analytic systems for plasma collection tubes, serving blood collection manufacturers globally. The Metrix® COVID/Flu Test represents their molecular diagnostics portfolio, offering point-of-care detection and differentiation of SARS-CoV-2, Flu A, and Flu B with small footprint and streamlined workflow. Beyond products, SEKISUI offers Biopharma Services supporting biotherapeutic and pharmaceutical manufacturing, technical transfer, and process scale-up. The company serves core laboratories, healthcare providers, in vitro diagnostics manufacturers, and distributors. SEKISUI combines analytical accuracy with operational efficiency, positioning products for cost containment and outcome improvement across clinical settings. The organization emphasizes patient-centric diagnostic solutions and maintains comprehensive technical and educational support for laboratory and clinical professionals.